Epilepsy is a group of neurological disorders characterized by recurrent epileptic seizures with a prevalence rate of 0.5%-1% among children [1]. Most patients are successfully treated with anti-epileptic drugs, but about a third suffer from treatment-resistant epilepsy (TRE) [2]. Vagal nerve stimulation (VNS), approved by U.S Food and Drug Administration (USFDA) in 1997, is a safe and efficacious treatment for TRE, consisting of an implanted pacemaker-like generator and nerve stimulation electrodes, that delivers intermittent stimulation to the patient’s left vagus nerve [2].
14
JUL
JUL
0